Trial · NCT07498205
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
NCT07498205, Phase 4, Not yet recruiting, SWOG Cancer Research Network
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts. Trials, record NCT07498205. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07498205
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
- NCT number
- NCT07498205
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 268 participants, estimated
- Lead sponsor
- SWOG Cancer Research Network
- Conditions
- Myelofibrosis, Myelofibrosis (MF)
- Interventions
- Momelotinib, Ruxolitinib
- First posted
- 2026-03-27
- Last updated
- 2026-09-17
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To estimate and compare the proportion of participants achieving a dual response [SVR35] and transfusion independence response from red blood cell transfusions. | 24 weeks after randomization | To estimate and compare the proportion of patients achieving a dual response both spleen response \[SVR35\] and transfusion independence response \[TI-R\] from red blood cell transfusions at week 24 post-Step 1 randomization in JAK-inhibitor naïve participants with myelofibrosis treated with momelotinib versus ruxolitinib. |
| Secondary | TI-R Rate | 24 weeks after Step 1 Randomization | To estimate and compare the TI-R rate at week 24, post-Step 1 randomization in each treatment arm. |
| Secondary | SVR35 at week 24 post-randomization | 24 weeks after Step 1 Randomization | To estimate and compare the rates of SVR35 at week 24 post-randomization in each treatment arm. |
| Secondary | OS | 96 weeks after Step 1 Randomization | To estimate overall survival (OS) in each treatment arm. |
| Secondary | PFS | 96 weeks after Step 1 Randomization | To estimate progression-free survival (PFS) in each treatment arm. |
| Secondary | SVR35 at week 24 post-randomization | 24 weeks after Step 1 Randomization | To estimate and compare SVR35 at week 24 post-randomization in each treatment arm with a sensitivity analysis based on a modeled version of the continuous spleen response rate. |
| Secondary | Allogeneic Transplantation | 96 weeks after Step 1 Randomization | To tabulate the proportion of participants in each arm who undergo allogeneic transplantation at week 24 and week 48 post-Step 1 randomization. |
| Secondary | Cross-over | 72 weeks after Step 1 Randomization | To tabulate the number of participants on each arm who cross over. |
| Secondary | Time to next non-protocol treatment | 96 weeks after Step 1 Randomization | To estimate and compare the time to next non-protocol treatment (excludes crossover) in each treatment arm. |
| Secondary | SVR35 | 48 weeks after Step 1 Randomization | To estimate and compare the rates of SVR35 at week 48 post-Step 1 randomization by treatment arm and stratified by cross-over-status. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07498205
GET https://conductscience.org/api/trials/v1/NCT07498205/registered